We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Recovery Housing For Drug Dependent Pregnant Women (HOME)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00497302
First Posted: July 6, 2007
Last Update Posted: March 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Hendree E. Jones, Johns Hopkins University
  Purpose

For the past several years our research program has developed and tested an intensive outpatient intervention that is based in social learning theory and employs abstinence contingent access to recovery housing as a routine aspect of an intensive day treatment counseling program. The present project proposes to extend this treatment intervention to the special population of pregnant drug using women enrolled at the Center for Addiction and Pregnancy (CAP). We will compare an enhanced treatment that includes abstinence contingent recovery house living plus intensive individual therapy, to standard care at the CAP program. Specific aims of the project are derived from testing a two-group design are described below:

  1. To determine whether financially supported abstinence-contingent recovery house placement plus individual counseling in pregnant drug-dependent women improves prenatal outpatient treatment retention.
  2. To determine whether financially supported abstinence-contingent recovery house placement plus individual counseling in pregnant drug-dependent women reduces prenatal drug use.
  3. To determine whether financially supported abstinence-contingent recovery house placement plus individual counseling results in better maternal and infant clinical birth outcomes (e.g., birth weight, estimated gestational age (EGA) at delivery, medical complications).

Condition Intervention Phase
Drug Addiction Behavioral: RBT Behavioral: usual care Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Recovery Housing For Drug Dependent Pregnant Women

Further study details as provided by Hendree E. Jones, Johns Hopkins University:

Primary Outcome Measures:
  • Treatment retention, drug free urine samples at follow-up and delivery [ Time Frame: treatment entry until 12 months post treatment entry ]

Secondary Outcome Measures:
  • prenatal care compliance, neonatal and birth outcomes [ Time Frame: treatment entry until 12 months post treatment entry ]

Enrollment: 128
Study Start Date: November 2004
Study Completion Date: August 2009
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
receives housing based on drug abstinence
Behavioral: RBT
Contingency management and behavioral counseling including motivational interviewing
Active Comparator: 2
Usual care treatment at the Center for Addiction and Pregnancy
Behavioral: usual care
receives usual comprehensive care at Center for Addiction and Pregnancy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CAP enrolled
  • Age 18 or older
  • Evidence of use of opiate and/or cocaine use in the past 30 days
  • Assigned to pharmacotherapy free modality
  • CAP admission at an estimated gestational age (EGA) <34 weeks

Exclusion criteria:

  • Endorses current suicidal ideation
  • Any medical disorders requiring extended or future hospitalization
  • Meet diagnostic criteria for current DSM-IV alcohol dependence
  • Meet diagnostic criteria for a current DSM-IV Axis I thought disorder (i.e. schizophrenia)
  • Demonstrate significant cognitive impairment that precludes them from completing the initial assessment battery
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00497302


Locations
United States, Maryland
Center for Addiction and Pregnancy Jhons Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Hendree E Jones, PhD Johns Hopkins University
  More Information

Responsible Party: Hendree E. Jones, Adjunct Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00497302     History of Changes
Other Study ID Numbers: R01DA014979 ( U.S. NIH Grant/Contract )
DPMCDA
First Submitted: July 5, 2007
First Posted: July 6, 2007
Last Update Posted: March 5, 2013
Last Verified: March 2013

Keywords provided by Hendree E. Jones, Johns Hopkins University:
cocaine
opiate
pregnancy
post-partum
neonatal abstinence syndrome
contingency management
Reinforcement Based Treatment
women

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders